Zobrazeno 1 - 10
of 24
pro vyhledávání: '"J. W. Wilmink"'
Autor:
L. A. Daamen, I. W. J. M. van Goor, V. P. Groot, P. C. M. Andel, L. A. A. Brosens, O. R. Busch, G. A. Cirkel, N. Haj Mohammad, H. D. Heerkens, I. H. J. T. de Hingh, F. Hoogwater, H. W. M. van Laarhoven, M. Los, G. J. Meijer, V. E. de Meijer, R. Pande, K. J. Roberts, J. Stoker, M. W. J. Stommel, G. van Tienhoven, R. C. Verdonk, H. M. Verkooijen, F. J. Wessels, J. W. Wilmink, M. G. Besselink, H. C. van Santvoort, M. P. W. Intven, I. Q. Molenaar, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-18 (2024)
Abstract Background Disease recurrence remains one of the biggest concerns in patients after resection of pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most patients experience local and/or distant PDAC recurrence w
Externí odkaz:
https://doaj.org/article/ba5d1663657942199349b99fc6296573
Autor:
L. A. Daamen, I. W. J. M. van Goor, V. P. Groot, P. C. M. Andel, L. A. A. Brosens, O. R. Busch, G. A. Cirkel, N. Haj Mohammad, H. D. Heerkens, I. H. J. T. de Hingh, F. Hoogwater, H. W. M. van Laarhoven, M. Los, G. J. Meijer, V. E. de Meijer, R. Pande, K. J. Roberts, J. Stoker, M. W. J. Stommel, G. van Tienhoven, R. C. Verdonk, H. M. Verkooijen, F. J. Wessels, J. W. Wilmink, M. G. Besselink, H. C. van Santvoort, M. P. W. Intven, I. Q. Molenaar, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/df249c70ed7544c39ba98d65b3adf85a
Autor:
J. L. van Dam, E. M. M. Verkolf, E. N. Dekker, B. A. Bonsing, S. O. Bratlie, L. A. A. Brosens, O. R. Busch, L. M. J. W. van Driel, C. H. J. van Eijck, S. Feshtali, P. Ghorbani, D. J. A. de Groot, J. W. B. de Groot, B. C. M. Haberkorn, I. H. de Hingh, B. van der Holt, T. M. Karsten, M. B. van der Kolk, K. J. Labori, M. S. L. Liem, O. J. L. Loosveld, I. Q. Molenaar, M. B. Polée, H. C. van Santvoort, J. de Vos – Geelen, M. L. Wumkes, G. van Tienhoven, M. Y. V. Homs, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, for the Dutch Pancreatic Cancer Group
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvan
Externí odkaz:
https://doaj.org/article/9bd0b84a5c244ba18797a99563ce5af4
Autor:
D. Doppenberg, M. G. Besselink, C. H. J. van Eijck, M. P. W. Intven, B. Groot Koerkamp, G. Kazemier, H. W. M. van Laarhoven, M. Meijerink, I. Q. Molenaar, J. J. M. E. Nuyttens, R. van Os, H. C. van Santvoort, G. van Tienhoven, H. M. Verkooijen, E. Versteijne, J. W. Wilmink, F. J. Lagerwaard, A. M. E. Bruynzeel
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Significant comorbidities, advanced age, and a poor performance status prevent surgery and systemic treatment for many patients with localized (non-metastatic) pancreatic ductal adenocarcinoma (PDAC). These patients are currently
Externí odkaz:
https://doaj.org/article/c73bd68aed71460cbe9d36d02915a990
Autor:
S. M. Haenen, J. A. M. G. Tol, S. C. J. van Steen, O. R. Busch, A. Farine Sarasqueta, S. Roshani, A. Wolkerstorfer, M. M. D. van der Linden, J. W. Wilmink, H. C. Post, M. G. Besselink
Publikováno v:
Journal of Medical Case Reports, Vol 16, Iss 1, Pp 1-4 (2022)
Abstract Background Pancreatic panniculitis is characterized by subcutaneous fat necrosis and is a rare presentation of an underlying pancreatic disease, appearing in approximately 2–3% of all patients with a pancreatic disease. The nodules usually
Externí odkaz:
https://doaj.org/article/60d630b31f3a455999ba9924a56e5a03
Autor:
I. W. J. M. van Goor, L. A. Daamen, M. G. Besselink, A. M. E. Bruynzeel, O. R. Busch, G. A. Cirkel, B. Groot Koerkamp, N. Haj Mohammed, H. D. Heerkens, H. W. M. van Laarhoven, G. J. Meijer, J. Nuyttens, H. C. van Santvoort, G. van Tienhoven, H. M. Verkooijen, J. W. Wilmink, I. Q. Molenaar, M. P. W. Intven, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-13 (2022)
Abstract Background Disease recurrence is the main cause of mortality after resection of pancreatic ductal adenocarcinoma (PDAC). In 20–30% of resected patients, isolated local PDAC recurrence occurs. Retrospective studies have suggested that stere
Externí odkaz:
https://doaj.org/article/8a61da727e0c449d953316f7b4843f0c
Autor:
D. Doppenberg, F. J. Lagerwaard, S. van Dieren, M. R. Meijerink, J. J. van der Vliet, M. G. Besselink, G. van Tienhoven, E. Versteijne, B. J. Slotman, J. W. Wilmink, G. Kazemier, A. M. E. Bruynzeel
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe role of stereotactic ablative radiation therapy (SABR) as local treatment option after chemotherapy for locally advanced pancreatic cancer (LAPC) is evolving. However adequate patient selection criteria for SABR in patients with LAPC ar
Externí odkaz:
https://doaj.org/article/6e519831ffaa433896a1e76b9092b0f2
Autor:
M. S. Walma, S. J. Rombouts, L. J. H. Brada, I. H. Borel Rinkes, K. Bosscha, R. C. Bruijnen, O. R. Busch, G. J. Creemers, F. Daams, R. M. van Dam, O. M. van Delden, S. Festen, P. Ghorbani, D. J. de Groot, J. W. B. de Groot, N. Haj Mohammad, R. van Hillegersberg, I. H. de Hingh, M. D’Hondt, E. D. Kerver, M. S. van Leeuwen, M. S. Liem, K. P. van Lienden, M. Los, V. E. de Meijer, M. R. Meijerink, L. J. Mekenkamp, C. Y. Nio, I. Oulad Abdennabi, E. Pando, G. A. Patijn, M. B. Polée, J. F. Pruijt, G. Roeyen, J. A. Ropela, M. W. J. Stommel, J. de Vos-Geelen, J. J. de Vries, E. M. van der Waal, F. J. Wessels, J. W. Wilmink, H. C. van Santvoort, M. G. Besselink, I. Q. Molenaar, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background Approximately 80% of patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy, of whom approximately 10% undergo a resection. Cohort studies investigating local tumor ablation with radiofrequency ablat
Externí odkaz:
https://doaj.org/article/3d301f6bd2bd4bac89f7f45ee7d3f040
Autor:
Q. P. Janssen, J. L. van Dam, B. A. Bonsing, H. Bos, K. P. Bosscha, P. P. L. O. Coene, C. H. J. van Eijck, I. H. J. T. de Hingh, T. M. Karsten, M. B. van der Kolk, G. A. Patijn, M. S. L. Liem, H. C. van Santvoort, O. J. L. Loosveld, J. de Vos-Geelen, B. M. Zonderhuis, M. Y. V. Homs, G. van Tienhoven, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, for the Dutch Pancreatic Cancer Group
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are hi
Externí odkaz:
https://doaj.org/article/c4666a70be2f4516b363089ddb9e6b2b
Autor:
T. M. Mackay, F. J. Smits, A. E. J. Latenstein, A. Bogte, B. A. Bonsing, H. Bos, K. Bosscha, L. A. A. Brosens, L. Hol, O. R. C. Busch, G. J. Creemers, W. L. Curvers, M. den Dulk, S. van Dieren, L. M. J. W. van Driel, S. Festen, E. J. M. van Geenen, L. G. van der Geest, D. J. A. de Groot, J. W. B. de Groot, N. Haj Mohammad, B. C. M. Haberkorn, J. T. Haver, E. van der Harst, G. J. M. Hemmink, I. H. de Hingh, C. Hoge, M. Y. V. Homs, N. C. van Huijgevoort, M. A. J. M. Jacobs, E. D. Kerver, M. S. L. Liem, M. Los, H. Lubbinge, S. A. C. Luelmo, V. E. de Meijer, L. Mekenkamp, I. Q. Molenaar, M. G. H. van Oijen, G. A. Patijn, R. Quispel, L. B. van Rijssen, T. E. H. Römkens, H. C. van Santvoort, J. M. J. Schreinemakers, H. Schut, T. Seerden, M. W. J. Stommel, A. J. ten Tije, N. G. Venneman, R. C. Verdonk, J. Verheij, F. G. I. van Vilsteren, J. de Vos-Geelen, A. Vulink, C. Wientjes, F. Wit, F. J. Wessels, B. Zonderhuis, C. H. van Werkhoven, J. E. van Hooft, C. H. J. van Eijck, J. W. Wilmink, H. W. M. van Laarhoven, M. G. Besselink, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-18 (2020)
Abstract Background Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified but their implementation in daily clinical practice is often suboptimal
Externí odkaz:
https://doaj.org/article/778d6790076f4b19a04ca4000032fef5